Dalbavancin

Drugs

Volumn 68, Issue 5, 2008, Pages 639-648

  Anderson, Vanessa R ^a,b   Keating, Gillian M ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Adis Drug Profiles; Dalbavancin, general; Research and development; Skin and soft tissue infections

Indexed keywords

AZTREONAM; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; FENTANYL; FUROSEMIDE; LINEZOLID; MACROLIDE; METRONIDAZOLE; MIDAZOLAM; OXACILLIN; PARACETAMOL; PENICILLIN G; PROTON PUMP INHIBITOR; SIMVASTATIN; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

ABNORMAL LABORATORY RESULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBACTERIAL ACTIVITY; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GRAM POSITIVE BACTERIUM; HEADACHE; HUMAN; INJECTION SITE REACTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOPENIA; LIVER FUNCTION TEST; LOOSE FECES; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; PANCYTOPENIA; PHARMACODYNAMICS; RASH; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; THROMBOCYTOPENIA; VAGINA MYCOSIS; VOMITING;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN DISEASES, BACTERIAL; TEICOPLANIN;

POSIBACTERIA;

EID: 41349116550     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868050-00006     Document Type: Review

References (35)

1. Fung HB, Chang JY, Kuczynski S. A practical guide to the treatment of complicated skin and soft tissue infections. Drugs 2003; 63 (14): 1459-80
2. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections [published erratum appears in Clin Infect Dis 2005 Dec 15; 41: 1830]. Clin Infect Dis 2005 Nov 15; 41 (10): 1373-406
3. Gemmell CG, Edwards DI, Fraise AP, et al. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 2006 Apr; 57 (4): 589-608
4. Van Bambeke F, Van Laethem Y, Courvalin P, et al. Glycopeptide antibiotics: from conventional molecules to new derivatives. Drugs 2004; 64 (9): 913-36
5. Gales AC, Sader HS, Jones RN. Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres. Clin Microbiol Infect 2005 Feb; 11 (2): 95-100
6. Buckwalter M, Dowell JA. Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. J Clin Pharmacol 2005 Nov; 45 (11): 1279-87
7. Data on file. Pfizer. 2007 Jun 19
8. Biedenbach DJ, Ross JE, Fritsche TR, et al. Activity of dalbavancin tested against Staphylococcus spp. and β-haemolytic Streptococcus spp. isolated from fifty-two geographically diverse medical centers in the United States. J Clin Microbiol 2007 Mar; 45 (3): 998-1004
9. Streit JM, Fritsche TR, Sader HS, et al. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn Microbiol Infect Dis 2004 Feb; 48 (2): 137-43
10. Streit JM, Sader HS, Fritsche TR, et al. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens. Diagn Microbiol Infect Dis 2005 Dec; 53 (4): 307-10
11. Jones RN, Fritsche TR, Sader HS, et al. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol. J Chemother 2005 Dec; 17 (6): 593-600
12. Bozdogan B, Ednie L, Credito K, et al. Derivatives of a vancomycin-resistant Staphylococcus aureus strain isolated at Hershey Medical Center. Antimicrob Agents Chemother 2004 Dec; 48 (12): 4762-5
13. Jones RN, Stilwell MG, Sader HS, et al. Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004). Diagn Microbiol Infect Dis 2006 Feb; 54 (2): 149-53
14. Goldstein EJ, Citron DM, Warren YA, et al. In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic Gram-positive isolates recovered from diabetic foot infections. Antimicrob Agents Chemother 2006 Aug; 50 (8): 2875-9
15. Lin G, Credito K, Ednie LM, et al. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob Agents Chemother 2005 Feb; 49 (2): 770-2
16. Lopez S, Hackbarth C, Romano G, et al. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide. J Antimicrob Chemother 2005 Mar; 55 (Suppl. S2): ii21-4
17. Dorr MB, Jabes D, Cavaleri M, et al. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J Antimicrob Chemother 2005 Mar; 55 Suppl. 2: ii25-30
18. Goldstein BP, Jones RN, Fritsche TR, et al. Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections. Diagn Microbiol Infect Dis 2006 Feb; 54 (2): 83-7
19. Lefort A, Pavie J, Garry L, et al. Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin. Antimicrob Agents Chemother 2004 Mar; 48 (3): 1061-4
20. Jabes D, Candiani G, Romano G, et al. Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model. Antimicrob Agents Chemother 2004 Apr; 48 (4): 1118-23
21. Leighton A, Gottlieb AB, Dorr MB, et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother 2004 Mar; 48 (3): 940-5
22. Seltzer E, Dorr MB, Goldstein BP, et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 2003 Nov 15; 37 (10): 1298-303
23. Andes D, Craig WA. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob Agents Chemother 2007 May; 51 (5): 1633-42
24. Bowker KE, Noel AR, MacGowan AP. Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system. J Antimicrob Chemother 2006 Oct; 58 (4): 802-5
25. Goldstein BP, Seltzer E, Flamm RK, et al. Dalbavancin (DAL) phase 3 skin and skin structure (SSSI) studies: pathogens and microbiological efficacy [abstract no. L-1577]. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005 Dec 16-19; Washington, DC
26. Dowell JA, Gottlieb AB, Van Saders C, et al. The pharmacokinetics and renal excretion of dalbavancin in healthy subjects [abstract no. A-1386 plus poster]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27-30; San Diego (CA), 18
27. Nicolau DP, Sun HK, Seltzer E, et al. Pharmacokinetics of dalbavancin in plasma and skin blister fluid. J Antimicrob Chemother 2007 Sep; 60 (3): 681-4
28. Dowell JA, Seltzer E, Buckwalter M, et al. The pharmacokinetics of dalbavancin (DAL) in subjects with mild, moderate or severe hepatic impairment (HI) [abstract no. A-19 plus poster]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30-Nov 2; Washington, DC, 4
29. Dowell J, Seltzer E, Stogniew M, et al. Dalbavancin dosage adjustments not required for patients with mild renal impairment [abstract no. P1224]. Clin Microbiol Infect 2003; 9 Suppl. 1: 291
30. Dowell J, Seltzer E, Stogniew MB, et al. Dalbavancin (DAL) pharmacokinetics (PK) in subjects with mild or moderate hepatic impairment (HI) [abstract no. A-19 plus poster]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14-17; Chicago (IL), 4
31. Dowell JA, Buckwalter M, Seltzer E, et al. Dalbavancin penetration into skin supports once weekly dosing [abstract no. P895]. Clin Microbiol Infect 2005 Apr; 11 (Suppl. 2): 272
32. Cavaleri M, Riva S, Valagussa A, et al. Pharmacokinetics and excretion of dalbavancin in the rat. J Antimicrob Chemother 2005 Mar; 55 Suppl. 2: ii31-5
33. Nord CE, Rasmanis G, Wahlund E. Effect of dalbavancin on the normal intestinal microflora. J Antimicrob Chemother 2006 Sep; 58 (3): 627-31
34. Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005 Nov 15; 41 (10): 1407-15
35. Carmeli Y, Rothermel C, Sheehan D, et al. Analysis of patients with community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) in a phase 3 study of dalbavancin (DAL) versus linezolid (LNZ) for the treatment of complicated skin and soft tissue infections (cSSTI) [abstract no. L-1211 plus poster]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco (CA), 374